Ganetespib potently reduced cell viability in vitro in a panel of CRC cell lines, with drug exposure resulting in the dose-dependent destabilization of multiple HSP90 client proteins, including MET, EGFR, IGF-1R and AKT. Here, MET is linked to colorectal carcinoma.